Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study
Ning Lyu, Yanan Kong, Xiaoxian Li, Luwen Mu, Haijing Deng, Huiming Chen, Meng Xiao He, Jinfa Lai, Jibin Li, Hailin Tang, Youen Lin, Ming Zhao
Abstract
The anti-programmed cell death protein-1 (PD-1) inhibitor is one of the second-line therapies for advanced hepatocellular carcinoma (HCC) after sorafenib failure. The goal of this study is to evaluate the feasibility and safety of ablation on the tumor in patients with advanced HCC who had stable disease or atypical response during single anti-PD-1 therapy after sorafenib failure. Atypical response defined as mixed responses in different lesions of the same individual (e.g., active or stable lesions mixed with progressive lesions).
Topics & Concepts
MedicineSorafenibPembrolizumabNivolumabHepatocellular carcinomaInternal medicineProgressive diseaseOncologyComplete responseAdverse effectGastroenterologyProgression-free survivalSurgeryDiseaseImmunotherapyOverall survivalCancerChemotherapyHepatocellular Carcinoma Treatment and PrognosisPancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers